Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis

被引：69

作者：

Gertz, Morie ^{[1
]}

Lacy, Martha ^{[1
]}

Dispenzieri, Angela ^{[1
]}

Hayman, Suzanne ^{[1
]}

Kumar, Shaji ^{[1
]}

Buadi, Francis ^{[1
]}

Leung, Nelson ^{[1
]}

Litzow, Mark ^{[2
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

[2] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN 55905 USA

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 01期

关键词：

amyloidosis; multiple myeloma; restrictive cardiomyopathy; stem cell transplantation; troponin T;

D O I：

10.1080/10428190701684518

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The efficacy of stem cell transplantation in amyloidosis largely is determined by treatment-related mortality rates (range, 11-25%). Appropriate patient selection is essential to avoid this high mortality rate. Among 271 patients undergoing stem cell transplantation, troponin T was a powerful predictor of treatment-related mortality. Patients with troponin T levels of 0.06g/L or higher had a day-100 all-cause mortality rate of 28%. Patients with troponin T levels less than 0.06g/L had a day-100 all-cause mortality rate of 7% (P0.001). Troponin T levels should be measured in all patients before transplantation. Those with troponin T levels exceeding 0.06g/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials.

引用

页码：36 / 41

页数：6

共 43 条

[1] Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? [J].